Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials

Animal models and observational human data indicate that complement, including C5a, pathogenically participates in ischemia reperfusion (IR) injury that manifests as delayed graft function (DGF) following deceased donor kidney transplantation. We report on the safety/efficacy of anti-C5 monoclonal a...

Disgrifiad llawn

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awduron:	Bernd Schröppel, Enver Akalin, Mukta Baweja, Roy D. Bloom, Sander Florman, Michael J. Goldstein, Brandy Haydel, Donald E. Hricik, Sanjay Kulkarni, Matthew H. Levine, Anita Mehrotra, Anup Patel, Emilio D. Poggio, Lloyd E. Ratner, Ron Shapiro, Peter S. Heeger
Fformat:	Artigo
Iaith:	Saesneg
Cyhoeddwyd:	2019
Mynediad Ar-lein:	https://doi.org/10.1111/ajt.15580 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.15580
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Byddwch y cyntaf i adael sylw!

Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials

Eitemau Tebyg